Filed under: Newsletters, Bargain stocks, Stocks to Buy
“After its run to a new all-time high last month, Amylin (NASDAQ: AMLN) appears to be undergoing some upper level consolidation,” notes biotech specialist John McCamant.
Following a presentation by the firm’s CEO at a biotech conference, the editor of The Medical Technology Stock Letter concludes, “Management has made a compelling case why the stock’s current trading range should be just a weigh station on the way to an even loftier valuation.”
The advisor explains, “At the Newsmakers in the Biotech Industry Conference — which took place September 6 - CEO Dan Bradbury discussed the still unrealized growth potential of both Byetta and Symlin.”
Regarding Byetta, he notes that Mr. Bradbury indicated that over 85% of diabetes specialists have prescribed the drug at this point, we are now starting to see prescription growth among primary care physicians.”
Continue reading Amylin (AMLN): ‘Blockbuster potential’ in diabetes
Permalink | Email this | Comments
Entries (RSS)